{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T22:42:41Z","timestamp":1773096161567,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","award":["2023B01J1007"],"award-info":[{"award-number":["2023B01J1007"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8217061"],"award-info":[{"award-number":["8217061"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-12603-4","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:07:40Z","timestamp":1770268060000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative effectiveness of tenofovir versus entecavir combined with peginterferon Alfa-2b for functional cure in HBeAg-negative chronic hepatitis B: a propensity score-matched analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Pei-Pei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Shi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Jian","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Liang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-shuo","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"12603_CR1","doi-asserted-by":"crossref","unstructured":"Liu J, Liang W, Jing W, Liu M. Countdown to 2030: eliminating hepatitis B disease, China. Bull World Health Organ. 2019;97(3):230\u20138.","DOI":"10.2471\/BLT.18.219469"},{"key":"12603_CR2","doi-asserted-by":"crossref","unstructured":"Cornberg M, Lok AS, Terrault NA, Zoulim F. EASL-AASLD HBV treatment endpoints conference faculty 2019. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV treatment endpoints conference. J Hepatol. 2020;72(3):539\u2013557.","DOI":"10.1016\/j.jhep.2019.11.003"},{"key":"12603_CR3","doi-asserted-by":"crossref","unstructured":"Wong GLH, Gane E, Lok ASF. How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development? J Hepatol. 2022;76(6):1249\u201362.","DOI":"10.1016\/j.jhep.2021.11.024"},{"key":"12603_CR4","doi-asserted-by":"crossref","unstructured":"Lim SG, Baumert TF, Boni C, Gane E, Levrero M, Lok AS, et al. The scientific basis of combination therapy for chronic hepatitis B functional cure. Nat Rev Gastroenterol Hepatol. 2023;20(4):238\u201353.","DOI":"10.1038\/s41575-022-00724-5"},{"key":"12603_CR5","doi-asserted-by":"crossref","unstructured":"Huang D, Wu D, Wang P, Wang Y, Yuan W, Hu D, et al. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB. J Hepatol. 2022;77(1):42\u201354.","DOI":"10.1016\/j.jhep.2022.01.021"},{"key":"12603_CR6","doi-asserted-by":"crossref","unstructured":"Erken R, Loukachov VV, de Niet A, Jansen L, Stelma F, Helder JT. A prospective five-year follow-up after peg-Interferon plus nucleotide analogue treatment or no treatment in hbeag negative chronic hepatitis B patients. J Clin Exp Hepatol. 2022 May-Jun;12(3):735\u201344.","DOI":"10.1016\/j.jceh.2021.12.011"},{"key":"12603_CR7","doi-asserted-by":"crossref","unstructured":"Gao N, Guan G, Xu G, Wu H, Xie C, Mo Z, et al. Integrated HBV DNA and CccDNA maintain transcriptional activity in intrahepatic HBsAg-positive patients with functional cure following PEG-IFN-based therapy. Aliment Pharmacol Ther. 2023;58(10):1086\u201398.","DOI":"10.1111\/apt.17670"},{"key":"12603_CR8","doi-asserted-by":"crossref","unstructured":"Chu JH, Huang Y, Xie DY, Deng H, Wei J, Guan YJ, et al. Real-world study on HBsAg loss of combination therapy in HBeAg-negative chronic hepatitis B patients. J Viral Hepat. 2022;29(9):765\u201376.","DOI":"10.1111\/jvh.13722"},{"key":"12603_CR9","doi-asserted-by":"crossref","unstructured":"Gao N, Yu H, Zhang J, Mo Z, Chu J, Xie C, et al. Role of hepatitis B surface antibody in seroreversion of hepatitis B surface antigen in patients achieving hepatitis B surface antigen loss with pegylated interferon-based therapy. J Viral Hepat. 2022;29(10):899\u2013907.","DOI":"10.1111\/jvh.13734"},{"key":"12603_CR10","doi-asserted-by":"crossref","unstructured":"Wang P, Mo Z, Zhang Y, Guo C, Chikede TK, Chen D, et al. Serum IL-5 levels predict HBsAg seroclearance in patients treated with Nucleos(t)ide analogues combined with pegylated interferon. Front Immunol. 2023;13:1104329.","DOI":"10.3389\/fimmu.2022.1104329"},{"key":"12603_CR11","doi-asserted-by":"crossref","unstructured":"Guan G, Zhang T, Ning J, Tao C, Gao N, Zeng Z, et al. Higher TP53BP2 expression is associated with HBsAg loss in peginterferon-\u03b1-treated patients with chronic hepatitis B. J Hepatol. 2024;80(1):41\u201352.","DOI":"10.1016\/j.jhep.2023.09.039"},{"key":"12603_CR12","doi-asserted-by":"crossref","unstructured":"Hsu YC, Yeh ML, Wong GL, Chen CH, Peng CY, Buti M, et al. Incidences and determinants of functional cure during Entecavir or Tenofovir disoproxil fumarate for chronic hepatitis B. J Infect Dis. 2021;224(11):1890\u20139.","DOI":"10.1093\/infdis\/jiab241"},{"key":"12603_CR13","doi-asserted-by":"crossref","unstructured":"Yoshida K, Enomoto M, Tamori A, Nishiguchi S, Kawada N. Combination of Entecavir or Tenofovir with pegylated Interferon-\u03b1 for Long-Term reduction in hepatitis B surface antigen levels: Simultaneous, Sequential, or Add-on combination therapy. Int J Mol Sci. 2021;22(3):1456.","DOI":"10.3390\/ijms22031456"},{"key":"12603_CR14","doi-asserted-by":"crossref","unstructured":"Hsu YC, Jun DW, Peng CY, Yeh ML, Trinh H, Wong GL, et al. Effectiveness of Entecavir vs Tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort. Hepatol Int. 2022;16(6):1297\u2013307.","DOI":"10.1007\/s12072-022-10411-x"},{"key":"12603_CR15","unstructured":"Wang G, Fusheng W. Guidelines for the prevention and treatment of chronic hepatitis B. Shi Yong Gan Dan Bing Za Zhi. 2016;19(03):389\u2013400."},{"key":"12603_CR16","doi-asserted-by":"crossref","unstructured":"Koike K, Suyama K, Ito H, Itoh H, Sugiura W. Randomized prospective study showing the non-inferiority of Tenofovir to Entecavir in treatment-na\u00efve chronic hepatitis B patients. Hepatol Res. 2018;48(1):59\u201368.","DOI":"10.1111\/hepr.12902"},{"key":"12603_CR17","doi-asserted-by":"crossref","unstructured":"Tamaki N, Kurosaki M, Kirino S, Yamashita K, Osawa L, Sekiguchi S, et al. Hepatitis B surface antigen reduction as a result of switching from long-term Entecavir administration to Tenofovir. JGH Open. 2019;4(3):429\u201332.","DOI":"10.1002\/jgh3.12273"},{"key":"12603_CR18","doi-asserted-by":"crossref","unstructured":"Lin S, Fu Y, Wu W, Chen T, Chen N, Xun Z, et al. The efficacy of addition of Tenofovir disoproxil fumarate to Peg-IFN\u03b1-2b is superior to the addition of Entecavir in hbeag positive CHB patients with a poor response after 12 weeks of Peg-IFN\u03b1-2b treatment alone. Int J Med Sci. 2020;17(10):1458\u201363.","DOI":"10.7150\/ijms.45658"},{"key":"12603_CR19","doi-asserted-by":"crossref","unstructured":"Murata K, Asano M, Matsumoto A, Sugiyama M, Nishida N, Tanaka E, et al. Induction of IFN-\u03bb3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. Gut. 2018;67(2):362\u201371.","DOI":"10.1136\/gutjnl-2016-312653"},{"key":"12603_CR20","doi-asserted-by":"crossref","unstructured":"Tseng CH, Hsu YC, Chen TH, Ji F, Chen IS, Tsai YN, et al. Hepatocellular carcinoma incidence with Tenofovir versus Entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(12):1039\u201352.","DOI":"10.1016\/S2468-1253(20)30249-1"},{"key":"12603_CR21","doi-asserted-by":"crossref","unstructured":"Zheng C, Yan H, Zeng J, Cai S, Wu X. Comparison of pegylated interferon monotherapy and de Novo pegylated interferon plus Tenofovir combination therapy in patients with chronic hepatitis B. Infect Drug Resist. 2019;12:845\u201354.","DOI":"10.2147\/IDR.S195144"},{"key":"12603_CR22","doi-asserted-by":"crossref","unstructured":"Marcellin P, Ahn SH, Chuang WL, Hui AJ, Tabak F, Mehta R, et al. Predictors of response to Tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. Aliment Pharmacol Ther. 2016;44(9):957\u201366.","DOI":"10.1111\/apt.13779"},{"key":"12603_CR23","doi-asserted-by":"crossref","unstructured":"Yang S, Ma X, Cai C, Wang H, Xiao F, Yu C. Tenofovir disoproxil fumarate is superior to Entecavir in reducing hepatitis B surface antigen for chronic hepatitis B in china: 2-Year comprehensive comparative result of a matched comparative study. Front Med (Lausanne). 2021;8:637126.","DOI":"10.3389\/fmed.2021.637126"},{"key":"12603_CR24","doi-asserted-by":"crossref","unstructured":"Chu JH, Huang Y, Xie DY, et al. Real-world study on HBsAg loss of combination therapy in HBeAg-negative chronic hepatitis B patients. J Viral Hepat. 2022;29(9):765\u201376.","DOI":"10.1111\/jvh.13722"},{"key":"12603_CR25","doi-asserted-by":"crossref","unstructured":"Zhang PX, Tang QQ, Zhu J, et al. Predictive models for functional cure in patients with CHB receiving PEG-IFN therapy based on HBsAg quantification through meta-analysis. Hepatol Int. 2024;18(4):1110\u201321.","DOI":"10.1007\/s12072-024-10666-6"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12603-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12603-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12603-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:28:41Z","timestamp":1773059321000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12603-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12603"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12603-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"5 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. The protocols and consent forms were approved by the Research Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University, and written informed consent was obtained from all participants. The ethics committee approval number is [2019]02-332-01.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"517"}}